Please Wait.....
Report
Latin America Viral Vector Manufacturing Market Report and Forecast 2024-2032
Market Report I 2024-06-26 I 140 Pages I EMR Inc.
Latin America Viral Vector Manufacturing Market Report and Forecast 2024-2032
Latin America Viral Vector Manufacturing Market Size
The global viral vector manufacturing market was valued at USD 2.6 billion in 2023, with Latin America holding a significant market share. It is expected to grow at a CAGR of 19.74% during the forecast period of 2024-2032 and attain a market value of USD 13.5 billion by 2032, driven by the increasing awareness about gene therapy across the region.
Latin America Viral Vector Manufacturing Market Outlook
- In March 2024, the National Health Surveillance Agency (Anvisa) of Brazil approved the world's first gene therapy Biomarin's Roctavian for severe adults with hemophilia A. This approval may contribute to increased adoption of viral vector manufacturing in the region.
- The market is witnessing surge in mergers and acquisitions, projected to boost the market value in the forecast period. In March 2024, a foundation from the Brazilian government's Ministry of Health, and Caring Cross, anon-profit organisation collaborated to develop local manufacturing of (CAR)-T cell and stem cell gene therapies for oncology, infectious, and genetic diseases in Brazil.
- Brazil has seen a significant increase in the number of dengue cases over the past four years. As of 2024, there have been 232,900 reported cases and 161 deaths. This has created a demand for the development of new vaccines, leading to growth in the market.
Latin America Viral Vector Manufacturing Market Analysis
Viral vectors are efficient gene transfer vehicles that are commonly used by molecular biologists to manipulate a specific cell type or tissue for certain therapeutic purposes. Regulatory approvals play a pivotal role in the distribution of therapeutics, and diagnostics in the market among other healthcare products and services while adding credibility at the same time. The market is propelled by the approvals of newly developed gene therapies by the regulatory authorities in the region. For instance, in March 2024, the National Health Surveillance Agency (Anvisa) of Brazil approved world's first gene therapy Biomarin's Roctavian (valoctocogene roxaparvovec) for severe hemophilia A. The approval is expected to foster increased investments in local manufacturing capabilities and technologies, thereby, enhancing the Latin America viral vector manufacturing market share.
The market is witnessing strategic collaborations, which is supporting viral vector manufacturing and its application in various healthcare domains. For instance, in March 2024, a collaboration was announced by the Brazilian government's Ministry of Health foundation, Fundacao Oswaldo Cruz (Fiocruz) and Caring Cross, to support the advancement of local manufacturing of chimeric antigen receptor (CAR)-T cell and stem cell gene therapies for oncology, infectious, and genetic diseases in Brazil. This also includes CAR-T cell therapies for leukemia, lymphoma, and HIV infection. The Caring Cross is a non-profit organisation, aimed at improving the development of innovative medicines and providing access to advanced medicinal. Such partnerships are expected to boost the Latin America viral vector manufacturing market growth in the forecast period.
The market demand is also projected to be positively impacted by the rising infectious diseases in the region. For instance, Bueno Aires has registered around 232,900 dengue cases and 161 deaths within the first 8 weeks of 2024. This outbreak has been considered the worst in 4 years. Increasing cases of dengue in Argentina create a pressing need to develop a vaccine in the region to overcome this outbreak. This will contribute to the increased demand for vaccines and therapeutics in the region, propelling the Latin America viral vector manufacturing market size. The rising demand can attract investors and expansions in the facilities needed for the production of viral vectors, which are crucial for manufacturing certain types of vaccines. As a result, the market is poised to be driven by the pressing need to develop more advanced technologies to assist vaccine development.
Latin America Viral Vector Manufacturing Market Segmentation??
The report offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
Adenoviral Vectors
Adeno-Associated Viral (AAV) Vectors
Lentiviral Vectors
Retroviral Vectors
Others
Market Breakup by Application
Gene Therapy
Cell Therapy
Others
Market Breakup by Therapeutic Area
Oncological Disorders
Neurological Disorders
Metabolic Disorders
Immunological Disorders
Others
Market Breakup by End User
Research Organizations
Biotech and Pharmaceutical Companies
Others
Market Breakup by Country
Brazil
Argentina
Mexico
Others
Leading Players in the Latin America Viral Vector Manufacturing Market
The key features of the market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:?
- Lonza Group AG
- Merck KGaA
- Thermo Fisher Scientific Inc.
- Catalent, Inc.
- Danaher Corporation
- Sartorius AG
- Fujifilm Group
- Novartis AG
- Charles River Laboratories
- Laboratorios Liomont
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.?
FAQs
- What was the Latin America viral vector manufacturing market forecast outlook in 2024-2032?
The Latin America viral vector manufacturing market is expected to be driven by the rising demand for global market, which is anticipated to grow at a CAGR of 19.7% during the forecast period of 2024-2032 and is likely to reach a market value of USD 8.1 billion by 2032.
- What are the major factors aiding the Latin America viral vector manufacturing market demand? ?
The market is driven by the increasing awareness of biotechnology and gene therapy for the treatment of several diseases.
- What are the major Latin America viral vector manufacturing market trends??
The market growth is influenced by increasing collaboration and partnerships in the region. For instance, in March 2024, Caring Cross and Fiocruz collaborated to improve access to cell and gene therapies in the region.
- What are the various types of viral vector manufacturing?
Various types include adenoviral vectors, adeno-associated viral (AAV) vectors, lentiviral vectors, retroviral vectors, and others.
- What are the various applications of viral vector manufacturing?
Viral vector manufacturing has applications in gene therapy, cell therapy, and vaccines.
- What are the therapeutic areas of viral vector manufacturing?
Therapeutic areas include oncological disorders, neurological disorders, metabolic disorders, immunological disorders, and others.
- Who are the end users in the market?
End users in the market include research organizations, biotech and pharmaceutical companies, and others.
- What is the market segmentation by country??
The market segmentation by countries includes Brazil, Argentina, Mexico, and others.
- Who are the key players in the Latin America viral vector manufacturing market?
The key players in the market are Lonza Group AG, Merck KGaA, Thermo Fisher Scientific Inc., Catalent, Inc., Danaher Corporation, Sartorius AG, Fujifilm Group, Novartis AG, Charles River Laboratories, and Laboratorios Liomont.
Meta description
The Latin America viral vector manufacturing market size is poised for growth, driven by the expansion of the global market, which was valued at USD 2.6 billion in 2023 and is projected to grow at a CAGR of 19.74% during the forecast period of 2024-2032.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Latin America Viral Vector Manufacturing Market Overview
3.1 Latin America Viral Vector Manufacturing Market Historical Value (2017-2023)
3.2 Latin America Viral Vector Manufacturing Market Forecast Value (2024-2032)
4 Latin America Viral Vector Manufacturing Market Landscape*
4.1 Latin America Viral Vector Manufacturing: Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Latin America Viral Vector Manufacturing: Product Landscape
4.2.1 Analysis by Type
4.2.2 Analysis by Technology
5 Latin America Viral Vector Manufacturing Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.2.1 Strengths
5.2.2 Weaknesses
5.2.3 Opportunities
5.2.4 Threats
5.3 Porter's Five Forces Model
5.3.1 Bargaining Power of Suppliers
5.3.2 Bargaining Power of Buyers
5.3.3 Threat of New Entrants
5.3.4 Threat of Substitutes
5.3.5 Degree of Rivalry
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Latin America Viral Vector Manufacturing Market Segmentation (2017-2032)
6.1 Latin America Viral Vector Manufacturing Market (2017-2032) by Type
6.1.1 Market Overview
6.1.2 Adenoviral Vectors
6.1.3 Adeno-Associated Viral (AAV) Vectors
6.1.4 Lentiviral Vectors
6.1.5 Retroviral Vectors
6.1.6 Others
6.2 Latin America Viral Vector Manufacturing Market (2017-2032) by Application
6.2.1 Market Overview
6.2.2 Gene Therapy
6.2.3 Cell Therapy
6.2.4 Vaccines
6.3 Latin America Viral Vector Manufacturing Market (2017-2032) by Therapeutic Area
6.3.1 Market Overview
6.3.2 Oncological Disorders
6.3.3 Neurological Disorders
6.3.4 Metabolic Disorders
6.3.5 Immunological Disorders
6.3.6 Others
6.4 Latin America Viral Vector Manufacturing Market (2017-2032) by End User
6.4.1 Market Overview
6.4.2 Research Organizations
6.4.3 Biotech and Pharmaceutical Companies
6.4.4 Others
6.5 Latin America Viral Vector Manufacturing Market (2017-2032) by Country
6.5.1 Market Overview
6.5.2 Brazil
6.5.3 Argentina
6.5.4 Mexico
6.5.5 Others
7 Brazil Viral Vector Manufacturing Market (2017-2032)
7.1 Brazil Viral Vector Manufacturing Market (2017-2032) by Type
7.1.1 Market Overview
7.1.2 Adenoviral Vectors
7.1.3 Adeno-Associated Viral (AAV) Vectors
7.1.4 Lentiviral Vectors
7.1.5 Retroviral Vectors
7.1.6 Others
7.2 Brazil Viral Vector Manufacturing Market (2017-2032) by Application
7.2.1 Market Overview
7.2.2 Gene Therapy
7.2.3 Cell Therapy
7.2.4 Vaccines
7.3 Brazil Viral Vector Manufacturing Market (2017-2032) by Therapeutic Area
7.3.1 Market Overview
7.3.2 Oncological Disorders
7.3.3 Neurological Disorders
7.3.4 Metabolic Disorders
7.3.5 Immunological Disorders
7.3.6 Others
7.4 Brazil Viral Vector Manufacturing Market (2017-2032) by End User
7.4.1 Market Overview
7.4.2 Research Organizations
7.4.3 Biotech and Pharmaceutical Companies
7.4.4 Others
8 Argentina Viral Vector Manufacturing Market (2017-2032)
8.1 Argentina Viral Vector Manufacturing Market (2017-2032) by Type
8.1.1 Market Overview
8.1.2 Adenoviral Vectors
8.1.3 Adeno-Associated Viral (AAV) Vectors
8.1.4 Lentiviral Vectors
8.1.5 Retroviral Vectors
8.1.6 Others
8.2 Argentina Viral Vector Manufacturing Market (2017-2032) by Application
8.2.1 Market Overview
8.2.2 Gene Therapy
8.2.3 Cell Therapy
8.2.4 Vaccines
8.3 Argentina Viral Vector Manufacturing Market (2017-2032) by Therapeutic Area
8.3.1 Market Overview
8.3.2 Oncological Disorders
8.3.3 Neurological Disorders
8.3.4 Metabolic Disorders
8.3.5 Immunological Disorders
8.3.6 Others
8.4 Argentina Viral Vector Manufacturing Market (2017-2032) by End User
8.4.1 Market Overview
8.4.2 Research Organizations
8.4.3 Biotech and Pharmaceutical Companies
8.4.4 Others
9 Mexico Viral Vector Manufacturing Market (2017-2032)
9.1 Mexico Viral Vector Manufacturing Market (2017-2032) by Type
9.1.1 Market Overview
9.1.2 Adenoviral Vectors
9.1.3 Adeno-Associated Viral (AAV) Vectors
9.1.4 Lentiviral Vectors
9.1.5 Retroviral Vectors
9.1.6 Others
9.2 Mexico Viral Vector Manufacturing Market (2017-2032) by Application
9.2.1 Market Overview
9.2.2 Gene Therapy
9.2.3 Cell Therapy
9.2.4 Vaccines
9.3 Mexico Viral Vector Manufacturing Market (2017-2032) by Therapeutic Area
9.3.1 Market Overview
9.3.2 Oncological Disorders
9.3.3 Neurological Disorders
9.3.4 Metabolic Disorders
9.3.5 Immunological Disorders
9.3.6 Others
9.4 Mexico Viral Vector Manufacturing Market (2017-2032) by End User
9.4.1 Market Overview
9.4.2 Research Organizations
9.4.3 Biotech and Pharmaceutical Companies
9.4.4 Others
10 Regulatory Framework
11 Patent Analysis
11.1 Analysis by Type of Patent
11.2 Analysis by Publication Year
11.3 Analysis by Issuing Authority
11.4 Analysis by Patent Age
11.5 Analysis by CPC Analysis
11.6 Analysis by Patent Valuation
11.7 Analysis by Key Players
12 Funding and Investment Analysis
12.1 Analysis by Funding Instances
12.2 Analysis by Type of Funding
12.3 Analysis by Funding Amount
12.4 Analysis by Leading Players
12.5 Analysis by Leading Investors
12.6 Analysis by Geography
13 Partnership and Collaborations Analysis
13.1 Analysis by Partnership Instances
13.2 Analysis by Type of Partnership
13.3 Analysis by Leading Players
13.4 Analysis by Geography
14 Supplier Landscape
14.1 Market Share by Top 5 Companies
14.2 Lonza Group AG
14.2.1 Financial Analysis
14.2.2 Product Portfolio
14.2.3 Demographic Reach and Achievements
14.2.4 Mergers and Acquisitions
14.2.5 Certifications
14.3 Merck KGaA
14.3.1 Financial Analysis
14.3.2 Product Portfolio
14.3.3 Demographic Reach and Achievements
14.3.4 Mergers and Acquisitions
14.3.5 Certifications
14.4 Thermo Fisher Scientific Inc.
14.4.1 Financial Analysis
14.4.2 Product Portfolio
14.4.3 Demographic Reach and Achievements
14.4.4 Mergers and Acquisitions
14.4.5 Certifications
14.5 Catalent, Inc
14.5.1 Financial Analysis
14.5.2 Product Portfolio
14.5.3 Demographic Reach and Achievements
14.5.4 Mergers and Acquisitions
14.5.5 Certifications
14.6 Danaher Corporation
14.6.1 Financial Analysis
14.6.2 Product Portfolio
14.6.3 Demographic Reach and Achievements
14.6.4 Mergers and Acquisitions
14.6.5 Certifications
14.7 Sartorius AG
14.7.1 Financial Analysis
14.7.2 Product Portfolio
14.7.3 Demographic Reach and Achievements
14.7.4 Mergers and Acquisitions
14.7.5 Certifications
14.8 Fujifilm Group
14.8.1 Financial Analysis
14.8.2 Product Portfolio
14.8.3 Demographic Reach and Achievements
14.8.4 Mergers and Acquisitions
14.8.5 Certifications
14.9 Novartis AG
14.9.1 Financial Analysis
14.9.2 Product Portfolio
14.9.3 Demographic Reach and Achievements
14.9.4 Mergers and Acquisitions
14.9.5 Certifications
14.10 Charles River Laboratories
14.10.1 Financial Analysis
14.10.2 Product Portfolio
14.10.3 Demographic
14.10.4 Mergers and Acquisitions
14.10.5 Certifications
14.11 Laboratorios Liomont
14.11.1 Financial Analysis
14.11.2 Product Portfolio
14.11.3 Demographic Reach and Achievements
14.11.4 Mergers and Acquisitions
14.11.5 Certifications
15 Latin America Viral Vector Manufacturing Market - Distribution Model (Additional Insight)
15.1 Overview
15.2 Potential Distributors
15.3 Key Parameters for Distribution Partner Assessment
16 Key Opinion Leaders (KOL) Insights (Additional Insight)
17 Company Competitiveness Analysis (Additional Insight)
17.1 Very Small Companies
17.2 Small Companies
17.3 Mid-Sized Companies
17.4 Large Companies
17.5 Very Large Companies
18 Payment Methods (Additional Insight)
18.1 Government Funded
18.2 Private Insurance
18.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security